NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:
A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
646-817-2836
| Last Trade: | US$3.99 |
| Daily Change: | -0.01 -0.25 |
| Daily Volume: | 379,450 |
| Market Cap: | US$136.940M |
March 05, 2025 February 26, 2025 February 05, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
